Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 3 1

Status

Completed 18Terminated 6Recruiting 6Unknown 5Active not recruiting 3Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 31INDUSTRY 6NETWORK 2OTHER_GOV 1

Study Type

Interventional 5Observational 1

Sponsor

Cancer Type

Thoracic 2Head & Neck 1Genitourinary 1Dermatologic 1CNS 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Prostatic Neoplasms 1Peripheral Lung Tumor 1Keratosis, Actinic 1Head and Neck Neoplasms 1Glioma 1

Interventions

pembrolizumab 241Carboplatin 166Injections 138Paclitaxel 118Gemcitabine 116Bevacizumab 113Cisplatin 105Docetaxel 80Cyclophosphamide 77Pemetrexed 76Capecitabine 69Fluorouracil 67Oxaliplatin 65Fulvestrant 58Nivolumab 55fludarabine 54Cetuximab 52Leucovorin 51130-nm albumin-bound paclitaxel 48Dexamethasone 46Rituximab 41atezolizumab 37venetoclax 35Drug Therapy 35toripalimab 34enzalutamide 34Irinotecan 33durvalumab 32Prednisone 32Letrozole 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Recruiting × INDUSTRY × Therapeutics × Clear all
NCT07581184 2026-05-12

BActinium-1

Aktis Oncology, Inc.

Phase 1 Recruiting
138 enrolled
Genitourinary

Prostatic Neoplasms

NCT07020117 2026-04-21

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

Aktis Oncology, Inc.

Phase 1 Recruiting
150 enrolled
BreastHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Triple Negative Breast Neoplasms

NCT06448793 2025-12-04

Patient and Physician Preference Study in Resectable, Non-small Cell Lung Cancer Treatments

Bristol-Myers Squibb

Recruiting
55 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07137819 2025-08-22

EXACT-1

Aresus Pharma GmbH

Phase 3 Recruiting
280 enrolled
Dermatologic

Keratosis, Actinic

NCT05918783 2025-02-11

Padeliporfin VTP Using Robotic Assisted Bronchoscopy in Peripheral Lung Cancer

Impact Biotech Ltd

Phase 1 Recruiting
36 enrolled

Peripheral Lung Tumor

NCT06305910 2024-03-12

CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults

OX2 Therapeutics

Phase 1 Recruiting
24 enrolled
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡